Back to School: How biopharma can reboot drug development. Access exclusive analysis here

bluebird bio raises $101 million in IPO

Gene therapy company bluebird bio Inc. (NASDAQ:BLUE) raised $101 million in an IPO through the

Read the full 154 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE